✦ LIBER ✦

Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

✍ Scribed by Grzegorz Helbig, Marek Hus, Magdalena Hałasz, Marek Dudziński, Agnieszka Więcławek, Małgorzata Stachowicz, Anna Soja, Sławomira Kyrcz-Krzemień

Book ID: 113093604
Publisher: Springer US
Year: 2011
Tongue: English
Weight: 167 KB
Volume: 29
Category: Article
ISSN: 1357-0560
DOI: 10.1007/s12032-011-9831-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Success of short-term, higher-dose imati

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

✍ Joseph H. Butterfield 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 209 KB

Triptolide abrogates oncogene FIP1L1-PDG

Triptolide abrogates oncogene FIP1L1-PDGFRα addiction and induces apoptosis in hypereosinophilic syndrome

✍ Yanli Jin; Qi Chen; Zhongzheng Lu; Bo Chen; Jingxuan Pan 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 861 KB

Isolated molecular relapse in FIP1L1-PDG

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

✍ Massimo Breccia; Daniela Cilloni; Laura Cannella; Caterina Stefanizzi; Agostino 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 208 KB